Management of localized and locally advanced renal tumors. A contemporary review of current treatment options

Minerva Medica

Volumn 104, Issue 3, 2013, Pages 237-259

  Brookman May, S ^a   Langenhuijsen, J F ^b   Volpe, A ^c   Minervini, A ^d   Joniau, S ^e   Salagierski, M ^f   Roscigno, M ^g   Akdogan, B ^h   Vandromme, A ⁱ   Rodriguez Faba, O ^j   Marszalek, M ^k  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g AO Papa Giovanni XXIII ^*  (Italy)

^h HACETTEPE UNIVERSITY   (Turkey)

ⁱ KLINIKUM BRAUNSCHWEIG   (Germany)

^j FUNDACIÓ PUIGVERT   (Spain)

^k DANUBE HOSPITAL   (Austria)

more..

Author keywords

Ablation techniques; Carcinoma, renal cell; Nephrectomy

Indexed keywords

ALPHA INTERFERON; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HORMONE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MANNITOL; PAPAVERINE; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; RENIALE; SORAFENIB; SUNITINIB; TUMOR VACCINE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ADRENALECTOMY; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHRONIC KIDNEY DISEASE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; CRYOABLATION; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; GROUPS BY AGE; HEART DISEASE; HIGH RISK PATIENT; HUMAN; KIDNEY BIOPSY; KIDNEY CARCINOMA; KIDNEY FUNCTION; KIDNEY METASTASIS; LAPAROSCOPIC SURGERY; LASER SURGERY; LYMPH NODE DISSECTION; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; NEPHRON SPARING SURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL NEPHRECTOMY; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIMARY TUMOR; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RENAL PROTECTION; REOPERATION; ROBOT ASSISTED NEPHRON SPARING SURGERY; ROBOT ASSISTED PARTIAL NEPHRECTOMY; ROBOTICS; SENSITIVITY AND SPECIFICITY; SURGICAL APPROACH; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT INDICATION; TUMOR ENUCLEATION; TUMOR LOCALIZATION; ULTRASOUND SURGERY; UNNECESSARY PROCEDURE; URETER STENT; URINARY TRACT FISTULA;

CARCINOMA, RENAL CELL; CATHETER ABLATION; COMBINED MODALITY THERAPY; CRYOTHERAPY; HUMANS; KIDNEY NEOPLASMS; LAPAROSCOPY; NEPHRECTOMY; NEPHRONS; ORGAN SPARING TREATMENTS; ROBOTICS;

EID: 84882340585     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (148)

1. Crepel M, Jeldres C, Perrotte P, Capitanio U, Isbarn H, Shariat SF et al. Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma: a population-based assessment. Urology 2010;75:271-5.
2. Weight CJ, Larson BT, Fergany AF, Gao T, Lane BR, Campbell SC et al. Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cTlb renal masses. J Urol 2010;183:1317-23.
3. Thompson RH, Siddiqui S, Lohse CM, Leibovich BC, Russo P, Blute ML. Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors. J Urol 2009;182:2601-6.
4. Kim SP, Murad MH, Thompson RH, Boorjian SA, Weight CJ, Han LC et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol 2012 [Epub ahead of print].
5. Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A et al. A prospective, randomized EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011;59:543.
6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296.
7. Huang WC, Levey AS, Serio AM. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006;7:735.
8. Tan HJ, Norton EC, Ye Z, Hafez KS, Gore JL, Miller DC. Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA 2012;307:1629-35.
9. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58:398.
10. MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Cabungcal AM et al.; UCAN Systematic Review Reference Group; EAU Renal Cancer Guideline Panel. Systematic review of oncological outcomes following surgical management of localized renal cancer. Eur Urol 2012;61:972-93.
11. MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Cabungcal AM et al.; UCAN Systematic Review Reference Group; EAU Renal Cancer Guideline Panel. Systematic review of perioperative and quality-of-life outcomes following surgical management of localized renal cancer. Eur Urol 2012;62:1097-117.
12. Blom J H M, Van PH, Marechal JM, Jacqmin D, Schröder FH, De Prijck L et al. Radical Nephrectomy with and without Lymph-Node Dissection: Final Results of European Organization for Research and Treatment of Cancer (EORTC) Randomized Phase 3 Trial 30881. Eur Urol 2009;55:28-34.
13. Herrlinger A, Schrott KM, Schott G, Sigel A. What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma. J Urol 1991;146:1224-7.
14. Lane BR, Tiong HY, Campbell SC, Fergany AF, Weight CJ, Larson BT et al. Management of the adrenal gland during partial nephrectomy. J Urol 2009;181:2430-6.
15. Mickisch GH, Garin A, Van Poppel H, De Prijck L, Sylvester R; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomized trial. Lancet 2001;358:966-70.
16. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-9.
17. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al. Sunitinibversusinterferonalfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
18. Clinical trials.gov. Clinical trial to assess the importance of nephrectomy, [cited 2013 April 19]. Available at: http://clinicaltrials.gov/ct2/ show/NCT00930033?term=CARMENA&rank=l
19. Clinical trials.gov. Sunitinib and surgery in treating patients with localized or metastatic kidney cancer. [Available at http://clinicaltrials.gov/ ct2/show/NCT0 0849186?term=renal+cell+carcinoma+neoadjuvant+p hase+III&rank=6; http://clinicaltrials.gov/ct2/show/NCT01769885rterm= renal+cell+carcinoma+neoadjuv ant+phase+III&rank=5
20. Martinez-Salamanca JI, Huang WC, Millan I, Bertini R, Bianco FJ, Carballido JA et al. Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol 2011;59:120-7.
21. Weight CJ, Lieser G, Larson BT, Gao T, Lane BR, Campbell SC et al. Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours. Eur Urol 2010;58:293-8.
22. Marszalek M, Carini M, Chlosta P, Jeschke K, Kirkali Z, Knuchel R et al. Positive surgical margins after nephron-sparing surgery. Eur Urol 2012;61:757-63.
23. Gill IS, Kavoussi LR, Lane BR, Blute ML, Babineau D, Colombo JR Jr et al. Comparison of 1800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 2007;178:41-6.
24. Marszalek M, Meixl H, Polajnar M, Rauchenwald M, Jeschke K, Madersbacher S. Laparoscopic and open partialnephrectomy: a matched-pair comparison of 200 patients. Eur Urol 2009;55:1171-8.
25. Thomas AZ, Smyth L, Hennessey D, O'Kelly F, Moran D, Lynch TH. Zero Ischemia Laparoscopic Partial Thulium Laser Nephrectomy. J Endourol 2013 [Epub ahead of print].
26. Patel SG, Penson DF, Pabla B, Clark PE, Cookson MS, Chang SS et al. National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol 2012;187:816-21.
27. Patel HD, Mullins JK, Pierorazio PM, Jayram G, Cohen JE, Matlaga BR et al. Trends in Renal Surgery: Robotic Technology is Associated with Increased Use of Partial Nephrectomy. J Urol 2012 [Epub ahead of print].
28. Sutherland SE, Resnick MI, Maclennan GT, Goldman HB. Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter? J Urol 2002;167:61-4.
29. Simmons MN, Schreiber MJ, Gill IS. Surgical renal ischemia: a contemporary overview. J Urol 2008;180:19-30.
30. Crain DS, Spencer CR, Favata MA, Amling CL. Transureteral saline perfusion to obtain renal hypothermia: potential application in laparoscopic partialnephrectomy. JSLS 2004;8:217-22.
31. Janetschek G, Abdelmaksoud A, Bagheri F, Al-Zahrani H, Leeb K, Gschwendtner M. Laparoscopic partial nephrectomy in cold ischemia: renal artery perfusion. J Urol 2004;171:68-71.
32. Becker F, Van Poppel H, Hakenberg OW, Stief C, Gill I, Guazzoni G et al. Assessing the impact of ischaemiatime during partialnephrectomy. Eur Urol 2009;56:625-34.
33. Marszalek M, Meixl H, Pitzler C, Unger D, Rauchenwald M, Jeschke K et al. Periarterialpapaverine improves early postoperative renal function after retroperitoneoscopic partial nephrectomy. World J Urol 2011 [Epub ahead of print].
34. Marszalek M, Carini M, Chlosta P, Jeschke K, Kirkali Z, Kniichel R et al. Positive surgical margins after nephron-sparing surgery. Eur Urol 2012;61:757-63.
35. Castilla EA, Liou LS, Abrahams NA, Fergany A, Rybicki LA, Myles J et al. Prognostic importance of resection margin width after nephron-sparing surgery for renal cell carcinoma. Urology 2002;60:993-7.
36. Minervini A, Ficarra V, Rocco F, Antonelli A, Bertini R, Carmignani G et al.; SATURN Project-LUNA Foundation. Simple enucleation is equivalent to traditional partial nephrectomy for renal cell carcinoma: results of a nonrandomized, retrospective, comparative study. J Urol 2011;185:1604-10.
37. Laryngakis NA, Van Arsdalen KN, Guzzo TJ, Malkowicz SB. Tumorenucleation: a safe treatment alternative for renal cell carcinoma. Expert Rev Anticancer Ther 2011;11:893-9.
38. Minervini A, Serni S, Tuccio A, Siena G, Vittori G, Masieri L et al. Simple enucleation versus radical nephrectomy in the treatment of pTla and pTlb renal cell carcinoma. Ann Surg Oncol 2012;19:694-700.
39. Carini M, Minervini A, Masieri L, Lapini A, Semi S. Simple enucleation for the treatment of PTla renal cell carcinoma: our 20-year experience. Eur Urol 2006;50:1263-8; discussion 1269-71.
40. Carini M, Minervini A, Lapini A, Masieri L, Serni S. Simple enucleation for the treatment of renal cell carcinoma between 4 and 7 cm in greatest dimension: progression and long-term survival. J Urol 2006;175:2022-6; discussion 2026.
41. Minervini A, Serni S, Tuccio A, Raspollini MR, Di Cristofano C, Siena G et al. Local recurrence after tumour enucleation for renal cell carcinoma with no ablation of the tumour bed: results of a prospective single-centre study. BJU Int 2011;107:1394-9.
42. Van Poppel H, Joniau S. How important are surgical margins in nephron-sparing surgery? Eur Urol Suppl 2007;6:533-9.
43. Saranchuk JW, Touijer AK, Hakimian P, Snyder ME, Russo P. Partial nephrectomy for patients with a solitary kidney: the Memorial Sloan-Kettering experience. BJU Int 2004;94:1323-8.
44. Minervini A, Di Cristofano C, Lapini A, Marchi M, Lanzi F, Giubilei G et al. Histopathological analysis ofperitumoralpseudocapsule and surgical margins status after tumorenucleation for renal cell carcinoma. Eur Urol 2009;55:1410.
45. Ficarra V, Porta C. Il carcinoma renale. Basi per un moderno approccio multidisciplinare. Roma: II Pensiero Scientifico Editore; 2010.
46. Cambio AJ, Evans C. Management approaches to small renaltumours. BJUInt 2006;97:456-60.
47. Minervini A, Vittori G, Lapini A, Tuccio A, Siena G, Serni S et al. Morbidity of tumour enucleation for renal cell carcinoma (RCC): results of a single centre prospective study. BJU Int 2012;109:372-7.
48. Minervini A, Vittori G, Salvi M, Sebastianelli A, Tuccio A, Siena G et al. Analysis of surgical complications of renal tumorenucleation with standardized instruments and external validation of PADUA classification. Ann Surg Oncol [Epub ahead of print].
49. Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH et al. Guideline for management of the clinical Tl renal mass. J Urol 2009;182:1271-9.
50. Ljungberg B, Hanbury DC, Kuczyc MA, Hora M, Kuczyk MA, Merseburger AS et al. Renal cell carcinoma guideline. Eur Urol 2010;58:398-406.
51. Kates M, Badalato GM, Pitman M, McKiernan JM. Increased risk of overall and cardiovascular mortality after radical nephrectomy for renal cell carcinoma 2 cm or less. J Urol 2011;186:1247-53.
52. Klarenbach S, Moore RB, Chapman DW, Dong J, Braam B. Adverse renal outcomes in subjects undergoing nephrectomy for renal tumors: a populationbased analysis. Eur Urol 2011;59:333-9.
53. Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC et al. Radical nephrectomy for pTla renal masses may be associated with decreased overall survival compared with partial nehrectomy. J Urol 2008;179:468-71.
54. Touijer K, Jacqmin D, Kavoussi LR, Montorsi F, Patard JJ, Rogers CG et al. The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. Eur Urol 2010;57:214-22.
55. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 2000;75:1236-42.
56. Lane BR, Babineau DC, Poggio ED, Weight CJ, Larson BT, Gill IS et al. Factors predicting renal functional outcome after partial nephrectomy. J Urol 2008;180:2363-8, discussion 2368-9.
57. Song C, Bang JK, Park HK, Ahn H. Factors influencing renal function reduction after partial nephrectomy. J Urol 2009;181:48-53, discussion 53-4.
58. Funahashi Y, Hattori R, Yamamoto T, Kamihira O, Kato K, Gotoh M. Ischemic renal damage after nephron-sparing surgery in patients with normal contralateral kidney. Eur Urol 2009;55:209-16.
59. Huang WC, Elkin EB, Levey AS, Jang TL, Russo P. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors-is there a difference in mortality and cardiovascular outcomes? J Urol 2009;181:55-61; discussion 61-2.
60. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006;98:1331-4.
61. Chow W-H, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J 2008;14:288-301
62. Chow W-H, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999;281:1628-31.
63. Clayman RV, Kavoussi LR, Soper NJ, Dierks SM, Merety KS, Darcy MD et al. Laparoscopic nephrectomy. N Engl J Med. 1991;324:1370-1.
64. Burgess NA, Koo BC, Calvert RC, Hindmarsh A, Donaldson PJ, Rhodes M et al. Randomized trial of laparoscopic v open nephrectomy. J Endourol 2007;21:610-3.
65. Simmons MN, Chung BI, Gill IS. Perioperative efficacy of laparoscopic partial nephrectomy for tumors larger than 4 cm. Eur Urol 2009;55:199-208.
66. Hemal AK, Kumar A, Kumar R, Wadhwa P, Seth A, Gupta NP. Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. J Urol 2007;177:862-6.
67. Stewart GD, Ang WJ, Laird A, Tolley DA, Riddick AC, McNeill SA. The operative safety and oncological outcomes of laparoscopic nephrectomy for T3 renal cell cancer. BJU Int 2012;110:884-90.
68. Nambirajan T, Jeschke S, Al-Zahrani H, Vrabec G, Leeb K, Janetschek G. Prospective, randomized controlled study: transperitoneal laparoscopic versus retroperitoneoscopic radical nephrectomy. Urology 2004;64:919-24.
69. Desai MM, Strzempkowski B, Matin SF, Steinberg AP, Ng C, Meraney AM et al. Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy. J Urol 2005;173:38-41.
70. Nadler RB, Loeb S, Clemens JQ, Batler RA, Gonzalez CM, Vardi IY. A prospective study of laparoscopic radical nephrectomy for Tl tumors-is transperitoneal, retroperitoneal or hand assisted the best approach?J Urol 2006;175:1230-3.
71. Gabr AH, Gdor Y, Strope SA, Roberts WW, Wolf JS Jr. Approach and specimen handling do not influence oncological perioperative and long-term outcomes after laparoscopic radical nephrectomy. J Urol 2009;182:874-80.
72. Hemal AK, Kumar A. A prospective comparison of laparoscopic and robotic radical nephrectomy for T1-2N0M0 renal cell carcinoma. World J Urol 2009;27:89-94.
73. Soga N, Kato M, Masui S, Nishikawa K, Hasegawa Y, Yamada Y et al. Comparison of radical nephrectomy techniques in one center: minimal incision portless endoscopic surgery versus laparoscopic surgery. Int J Urol 2008;15:1018-21.
74. Bazzi WM, Stroup SP, Kopp RP et al. Comparison of laparoendoscopic single-site and multiport laparoscopic radical and partial nephrectomy: a prospective, nonrandomized study. Urology 2012;80:1039-45.
75. Wang L, Liu B, Wu Z, Yang Q, Chen W, Xu Z et al. A matched-pair comparison of laparoendoscopic single-site surgery and standard laparoscopic radical nephrectomy by a single urologist. J Endourol 2012;26:676-81.
76. Greco F, Veneziano D, Wagner S, Kawan F, Mohammed N, Hoda MR et al. Laparoendoscopic single-site radical nephrectomy for renal cancer: technique and surgical outcomes. Eur Urol 2012;62:168-74.
77. Winfield HN, Donovan JF, Godet AS, Clayman RV. Laparoscopic partial nephrectomy: initial case report for benign disease. J Endourol 1993;7:521-6.
78. Marszalek M, Meixl H, Polajnar M, Rauchenwald M, Jeschke K, Madersbacher S. Laparoscopic and Open Partial Nephrectomy: A Matched-Pair Comparison of 200 Patients. Eur Urol 2009;55:1171-8.
79. Porpiglia F, Volpe A, Billia M, Scarpa RM. Laparoscopic versus open partial nephrectomy: analysis of the current literature. Eur Urol 2008;53:732-43, discussion 742-3.
80. Colli J, Sartor O, Grossman L, Lee BR. Underutilization of partial nephrectomy for stage tl renal cell carcinoma in the United States, trends from 2000 to 2008. A long way to go. Clin Genitourin Cancer 2012;10:219-24.
81. Gettman MT, Blute ML, Chow GK, Neururer R, Bartsch G, Peschel R. Robotic-assisted laparoscopic partial nephrectomy: technique and initial clinical experience with Da Vinci robotic system. Urology 2004;64:914-8.
82. Benway BM, Bhayani SB, Rogers CG, Dulabon LM, Patel MN, Lipkin M et al. Robot assisted partial nephrectomy versus laparoscopic partial nephrectomy for renal tumors: a multi-institutional analysis of perioperative outcomes. J Urol 2009;182:866-72.
83. Patel MN, Krane LS, Bhandari A, Laungani RG, Shrivastava A, Siddiqui SA et al. Robotic partial nephrectomy for renal tumors larger than 4 cm. Eur Urol 2010;57:310-6.
84. Simhan J, Smaldone MC, Tsai KJ, Li T, Reyes JM, Canter D et al. Perioperative outcomes of robotic and open partial nephrectomy for moderately and highly complex renal lesions. J Urol 2012;187:2000-04.
85. Goldberg SN, Gazelle GS. Radiofrequency tissue ablation: physical principles and techniques for increasing coagulation necrosis. Hepatogastroenterology 2001;48:359-67.
86. Carey RI, Leveillee RJ. First prize: direct real-time temperature monitoring for laparoscopic and CT-guided radio-frequency ablation of renal tumors between 3 and 5 cm. J Endourol 2007;21:807-13.
87. Psutka SP, Feldman AS, McDougal WS, McGovern FJ, Mueller P, Gervais DA. Long-term oncologic outcomes after radiofrequency ablation for Tl renal cell carcinoma. Eur Urol 2013;63:486-92.
88. Olweny EO, Park SK, Tan YK, Best SL, Trimmer C, Cadeddu JA. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical Tla renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up. Eur Urol 2012;61:1156-61.
89. Zagoria RJ, Traver MA, Werle DM, Perini M, Hayasaka S, Clark PE. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am J Roentgenol 2007;189:429-36.
90. Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma: Part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol 2005;185:64-71.
91. Pandharipande PV, Gervais DA, Mueller PR, Hur C, Gazelle GS. Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysis. Radiology 2008;248:169-78.
92. Michaels MJ, Rhee HK, Mourtzinos AP, Summerhayes IC, Silverman ML, Libertino JA. Incomplete renal tumor destruction using radio frequency interstitial ablation. J Urol 2002;168:2406-9.
93. Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982-1997). Urology 2000;56:58-62.
94. Rodriguez Faba O, Rosales Bordes A, Salvador Bayarri J et al. Laparoscopic renal cryotherapy: preliminary experience. Actas Urol Esp 2009;33:982-7.
95. Rupp CC, Hoffmann NE, Schmidlin FR, Swanlund DJ, Bischof JC, Coad JE. Cryosurgical changes in the porcine kidney: histologic analysis with thermal history correlation. Cryobiology 2002;45:167-82.
96. Woolley ML, Schulsinger DA, Durand DB, Zeltser IS, Waltzer WC. Effect of freezing parameters (freeze cycle and thaw process) on tissue destruction following renal cryoablation. J Endourol 2002;16:519-22.
97. Young JL, McCormick DW, Kolla SB, Sountoulides PG, Kaufmann OG, Ortiz-Vanderdys CG et al. Are multiple cryoprobes additive or synergistic in renal cryotherapy? Urology 2012;79:484e481-486.
98. Puigvert F. Protocoloasistencialpara el tratamiento de masasrenalesmediantecrioterapia. [cited 2013 April 19]. Available at: wwwfundacio-puigvertes/protocolos 2011
99. Stein AJ, Mayes JM, Mouraviev V, Chen VH, Nelson RC, Polascik TJ. Persistent contrast enhancement several months after laparoscopic cryoablation of the small renal mass may not indicate recurrent tumor. J Endourol 2008;22:2433-9.
100. Beemster PW, Barwari K, Mamoulakis C, Wijkstra H, De La Rosette JJ, Laguna MP. Laparoscopic renal cryoablation using ultrathin 17-gauge cryoprobes: mid-term oncological and functional results. BJU Int 2011;108:577-82.
101. Aron M, Kamoi K, Remer E, Berger A, Desai M, Gill I. Laparoscopic renal cryoablation: 8-year, single surgeon outcomes. J Urol 2010;183:889-95.
102. Un YC, Turna B, Frota R, Aron M, Haber GP, Kamoi K et al. Laparoscopic partial nephrectomy versus laparoscopic cryoablation for multiple ipsilateral renal tumors. Eur Urol 2008;53:1210-6.
103. Desai MM, Aron M, Gill IS. Laparoscopic partial nephrectomy versus laparoscopic cryoablation for the small renal tumor. Urology 2005;66(5 Suppl):23-8.
104. Kaouk JH, Aron M, Rewcastle JC, Gill IS. Cryotherapy: clinical end points and their experimental foundations. Urology 2006;68(1 Suppl):38-44.
105. Hui GC, Tuncali K, Tatli S, Morrison PR, Silverman SG. Comparison of percutaneous and surgical approaches to renal tumor ablation: metaanalysis of effectiveness and complication rates. J Vasc Interv Radiol 2008;19:1311-20.
106. Finley DS, Beck S, Box G. Percutaneous and laparoscopic cryoablation of small renal masses. J Urol 2008;180:492-8; discussion 498.
107. Bandi G, Hedican S, Moon T, Lee FT, Nakada SY. Comparison of postoperative pain, convalescence, and patient satisfaction after laparoscopic and percutaneous ablation of small renal masses. J Endourol 2008;22:963-7.
108. Mues AC, Okhunov Z, Haramis G, D'Agostino H, Shingleton BW, Landman J. Comparison of percutaneous and laparoscopic renal cryoablation for small (<3.0 cm) renal masses. J Endourol 2010;24:1097-100.
109. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer 2007;109:1763-8.
110. Lane BR, Abouassaly R, Gao T, Weight CJ, Hernandez AV, Larson BT et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 2010;116:3119-26.
111. Smaldone MC, Kutikov A, Egleston BL, Canter DJ, Viterbo R, Chen DY et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer 2012;118:997-1006.
112. Jewett MA, Mattar K, Basiuk J, Morash CG, Pautler SE, Siemens DR et al. Active Surveillance of Small Renal Masses: Progression Patterns of Early Stage Kidney Cancer. Eur Urol 2011;60:39-44.
113. Crispen PL, Viterbo R, Fox EB, Greenberg RE, Chen DY, Uzzo RG. Delayed intervention of sporadic renal masses undergoing active surveillance. Cancer 2008;112:1051-7.
114. Ljungberg B, Bensalah K, Bex A, Canfield S, Dabestani S, Hofmann F et al. European Association of Urology; Guidelines on renal cell carcinoma. Update 2013 [Epub ahead of print].
115. Volpe A, Cadeddu JA, Cestari A, Gill IS, Jewett MA, Joniau S et al. Contemporary management of small renal masses. Eur Urol 2011;60:501-15.
116. Gill IS, Aron M, Gervais DA, Jewett MA. Clinical practice. Small renal mass. N Engl J Med 2010;362:624-34.
117. Volpe A, Jewett MA. The role of surveillance for small renal masses. Nat Clin Pract Urol 2007;4:2-3.
118. Herts BR, Baker ME. The current role of percutaneous biopsy in the evaluation of renal masses. Semin Urol Oncol 1995;13:254-61.
119. Volpe A, Finelli A, Gill IS, Jewett MA, Martignoni G, Polascik TJ et al. Rationale for percutaneous biopsy and histologic characterization of renal tumors. Eur Urol 2012 [Epub ahead of print].
120. Choudhary S, Rajesh A, Mayer NJ, Mulcahy KA, Haroon A. Renal oncocytoma: CT features cannot reliably distinguish oncocytoma from other renal neoplasms. Clin Radiol 2009;64(5):517-522.
121. Weight CJ, Kaouk JH, Hegarty NJ, Remer EM, O'Malley CM, Lane BR et al. Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors. J Urol 2008;179:1277-81; discussion 1281-1273.
122. Barocas DA, Rohan SM, Kao J, Gurevich RD, Del Pizzo JJ, Vaughan ED Jr et al. Diagnosis of renal tumors on needle biopsy specimens by histological and molecular analysis. J Urol 2006;176:1957-62.
123. Barocas DA, Mathew S, Del Pizzo JJ, Vaughan ED Jr, Sosa RE, Fine RG et al. Renal cell carcinoma subtyping by histopathology and fluorescence in situ hybridization on - a needle-biopsy specimen. BJU Int 2007;99:290-5.
124. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Surveillance following radical or partial neprectomy for renalcellcarcinoma. Curr Urol Rep 2005;6:7-18.
125. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase HI, randomised controlled trial. Lancet 2004;363:594-9.
126. Kjaer M, Iversen P, Hvidt V, Bruun E, Skaarup P, Bech Hansen J et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol 1987;21:285-9.
127. Pizzocaro G, Piva L, Di Fronzo G, Giongo A, Cozzoli A, Dormia E et al. Adjuvant medroxyprogsterone acetate to radical nephrectomy in renal cancer. 5-year results of a prospective randomized study. J Urol 1987;138:1379-81.
128. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
129. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C et al. Bevacizumab plus interferon a-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind Phase III trial. Lancet 2007;370:2103-11.
130. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A et al. Temsirolimus, interferon, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
131. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 2008;372:449-56.
132. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82.
133. Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008;111:5610-20.
134. Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA. The natural history of incidentally detected small renal masses. Cancer 2000;100:738-45.
135. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 2006;175:425-31.
136. Abouassaly R, Lane BR, Novick AC. Active surveillance of renal masses in elderly patients. J Urol 2008;180:505-8; discussion 508-509.
137. Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 2009;115:2844-52.
138. Rosales JC, Haramis G, Moreno J, Badani K, Benson MC, McKieman J et al. Active surveillance for renal cortical neoplasms. J Urol 2010;183:1698-702.
139. Jewett MA, Mattar K, Basiuk J, Morash CG, Pautler SE, Siemens DR et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol 2011;60:39-44.
140. Patel N, Cranston D, Akhtar MZ, George C, Jones A, Leiblich A. Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. BJU Int 2012;110:1270-5.
141. Shannon BA, Cohen RJ, De Bruto H, Davies RJ. The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses. J Urol 2008;180:1257-61; discussion 1261.
142. Schmidbauer J, Remzi M, Memarsadeghi M, Haitel A, Klingler HC, Katzenbeisser D et al. Diagnostic Accuracy of Computed Tomography-Guided Percutaneous Biopsy of Renal Masses. Eur Urol 2007;53:1003-11.
143. Lebret T, Poulain JE, Molinie V, Herve JM, Denoux Y, Guth A et al. Percutaneous core biopsy for renal masses: indications, accuracy and results. J Urol 2007;178(4 Pt 1):1184-1188; discussion 1188.
144. Maturen KE, Nghiem HV, Caoili EM, Higgins EG, Wolf JS Jr, Wood DP Jr. Renal mass core biopsy: accuracy and impact on clinical management. AJR Am J Roentgenol 2007;188:563-70.
145. Volpe A, Mattar K, Finelli A, Kachura JR, Evans AJ, Geddie WR et al. Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. J Urol 2008;180:2333-7.
146. Wang AJ, Bhayani SB. Robotic partial nephrectomy versus laparoscopic partial nephrectomy for renal cell carcinoma: single-surgeon analysis of >100 consecutive procedures. Urology 2009;73:306-10.
147. Veltri A, Garetto I, Tosetti I, Busso M, Volpe A, Pacchioni D et al. Diagnostic accuracy and clinical impact of imaging-guided needle biopsy of renal masses. Retrospective analysis on 150 cases. Eur Radiol 2011;21:393-401.
148. Leveridge MJ, Finelli A, Kachura JR, Evans A, Chung H, Shiff DA et al. Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol 2011;60:578-84.